A long non-coding RNA, Morrbid, controls how long circulating myeloid cells live, which is key to maintaining the proper balance between fighting infection and exacerbating inflammation . The discovery offers a potential therapeutic target for certain inflammatory disorders, such as asthma , Churg-Strauss syndrome and hypereosinophilic syndrome, that are characterized by abnormal myeloid cell lifespan.
